InMed Pharmaceuticals (INM) Operating Income (2022 - 2025)
Historic Operating Income for InMed Pharmaceuticals (INM) over the last 5 years, with Q3 2025 value amounting to -$1.8 million.
- InMed Pharmaceuticals' Operating Income fell 493.97% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.0 million, marking a year-over-year decrease of 1065.97%. This contributed to the annual value of -$7.9 million for FY2025, which is 304.87% up from last year.
- Latest data reveals that InMed Pharmaceuticals reported Operating Income of -$1.8 million as of Q3 2025, which was down 493.97% from -$1.8 million recorded in Q2 2025.
- InMed Pharmaceuticals' 5-year Operating Income high stood at -$485150.0 for Q2 2023, and its period low was -$6.5 million during Q2 2022.
- Its 5-year average for Operating Income is -$2.5 million, with a median of -$2.1 million in 2023.
- In the last 5 years, InMed Pharmaceuticals' Operating Income surged by 9255.9% in 2023 and then tumbled by 31929.53% in 2024.
- Quarter analysis of 5 years shows InMed Pharmaceuticals' Operating Income stood at -$4.3 million in 2021, then soared by 48.66% to -$2.2 million in 2022, then rose by 25.7% to -$1.6 million in 2023, then plummeted by 37.03% to -$2.3 million in 2024, then increased by 19.23% to -$1.8 million in 2025.
- Its Operating Income was -$1.8 million in Q3 2025, compared to -$1.8 million in Q2 2025 and -$2.1 million in Q1 2025.